A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction-associated steatotic liver disease
Shifang Tang , Jürgen Borlak
Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (2) : e70218
A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction-associated steatotic liver disease
•Performed comprehensive genomics across liver biopsies of 396 MASLD patients and identified patients with increased, decreased and unchanged FGF21 expression. | |
•Used genomic data from FGF21 transgenic, knock-out and animal MASLD models treated with synthetic FGF21 analogues to identify FGF21-mode-of-action and metabolic networks in human MASLD. | |
•Given the significant heterogeneity in FGF21 expression, not all patients will benefit from FGF21-based therapies. |
fibroblast growth factor-21 / fibrosis / inflammation / metabolic dysfunction-associated steatotic liver disease / metabolism
2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
/
| 〈 |
|
〉 |
PDF
